drugset
drugset / Trial / NCT02494479

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479 ↗

Phase 2 Completed 115 enrolled Cellceutix Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.

Timeline

Start
2015-08
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABACAVIR HYDROXYACETATE Small molecule 50 mg Oral
Comparator ABACAVIR HYDROXYACETATE Small molecule 100 mg Oral
Comparator ABACAVIR HYDROXYACETATE Small molecule 200 mg Oral

Indications

psoriasis